SCHEMBL29454349

SCHEMBL29454349

Cc1cc(N)c(Cl)c(Nc2ccc(F)cc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BPTF Q12830 1/20 0.41
MAPT P10636 4/20 0.41
GAA P10253 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
MEN1 O00255 1/20 0.38
PRKD3 O94806 1/20 0.38
EGFR P00533 1/20 0.38
PRKCG P05129 1/20 0.38
PRKCB P05771 1/20 0.38
SRC P12931 1/20 0.38
PRKCA P17252 1/20 0.38
PRKCH P24723 1/20 0.38
PRKCI P41743 1/20 0.38
PRKCE Q02156 1/20 0.38
KMT2A Q03164 1/20 0.38
PRKCQ Q04759 1/20 0.38
PRKCZ Q05513 1/20 0.38
PRKCD Q05655 1/20 0.38
PRKD1 Q15139 1/20 0.38
IDO1 P14902 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22231721 1.00 BPTF (0.41) BPTFMAPTGAATDP1MEN1
SCHEMBL29454181 0.88 GAA (0.53) MAPTGAATDP1MEN1EGFR
SCHEMBL22232177 0.88 GAA (0.53) MAPTGAATDP1MEN1EGFR
SCHEMBL22232474 0.87 NPC1 (0.44) MAPTGAATDP1MEN1KMT2A
SCHEMBL29454186 0.87 NPC1 (0.44) MAPTGAATDP1MEN1KMT2A
SCHEMBL31723242 0.85 RAPGEF4 (0.47) MAPTGAATDP1EGFRKDM4E
SCHEMBL29454124 0.85 RAPGEF4 (0.47) MAPTGAATDP1EGFRKDM4E
SCHEMBL22232610 0.84 RAPGEF4 (0.51) MAPTGAATDP1MEN1KMT2A
SCHEMBL31723230 0.84 RAPGEF4 (0.51) MAPTGAATDP1MEN1KMT2A
SCHEMBL29454076 0.84 RAPGEF4 (0.51) MAPTGAATDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545639-B2 3-substituted phenylamidine compounds, preparation and use thereof PI INDUSTRIES LTD. (IN) 2026-02-10 US claimed
US-12545639-B2 3-substituted phenylamidine compounds, preparation and use thereof PI INDUSTRIES LTD. (IN) 2026-02-10 US disclosed
EP-4647426-A2 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI Industries Ltd. (IN) 2025-11-12 EP disclosed
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2022-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF H1-3, PRMT7, PFAS BPTF 4192/4885MAPT 3811/4885GAA 1080/4885
US-12545639-B2 3-substituted phenylamidine compounds, preparation and use thereof CBR1, CBR3, HCCS BPTF 4697/4885MAPT 4483/4885GAA 2001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.